Anaplastic Large Cell Lymphoma Therapeutics Market Report 2026

The anaplastic large cell lymphoma therapeutics market size has grown strongly in recent years. It will grow from $11.69 billion in 2025 to $12.42 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to improvements in chemotherapy protocols, increased awareness of rare lymphomas, availability of CHOP-based treatment regimens, early adoption of monoclonal antibody therapies, expansion of oncology treatment centers.

The anaplastic large cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $15.72 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to growing development of novel biologics, rising clinical trial activity for rare lymphomas, increasing focus on precision oncology, expansion of immunotherapy pipelines, improved diagnostic accuracy for alcl. Major trends in the forecast period include increasing adoption of targeted antibody therapies, rising use of personalized treatment regimens, growing focus on relapsed and refractory alcl management, expansion of stem cell transplant utilization, enhanced emphasis on reduced toxicity treatment options.

The growing adoption of targeted therapies is expected to drive the growth of the anaplastic large cell lymphoma therapeutics market in the coming years. Targeted therapies are advanced treatments designed to specifically inhibit molecules or pathways that drive cancer progression, thereby minimizing damage to healthy cells. The demand for targeted therapies is increasing due to advancements in precision medicine, expanding clinical research and innovations, and rising cancer incidence. Targeted therapies support ALCL treatment by selectively attacking cancer cells with specific molecular alterations, such as ALK gene rearrangements or CD30 expression, enhancing treatment efficacy, reducing systemic toxicity, and improving patient outcomes through precision medicine approaches. For example, in July 2023, a report by the American Society of Gene & Cell Therapy (ASGCT) and Citeline noted that the number of gene therapies in Phase II rose from 247 at the end of Q1 2023 to 260 by the end of Q2, reflecting a 5% increase. Consequently, the growing adoption of targeted therapies is fueling market growth in ALCL therapeutics.

Key companies in the ALCL therapeutics market are investing in clinical trials to improve treatment efficacy and expand therapeutic options. Clinical trial investments involve allocating financial and resource commitments to develop, test, and evaluate new drugs, therapies, or medical devices to ensure their safety, efficacy, and regulatory approval. For instance, in November 2023, March Biosciences, a US-based clinical-stage cell therapy company, received a $4.8 million investment from the Cancer Focus Fund to support its Phase 2 clinical trial of MB-105, a novel CAR-T therapy targeting CD5 for relapsed T-cell leukemias and lymphomas. The open-label, multi-center trial aims to evaluate MB-105 in patients with CD5-positive relapsed or refractory T-cell lymphoma. March Biosciences anticipates that MB-105 could become a first-in-class, life-saving therapy for patients with limited treatment options.

In June 2024, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company, partnered with Pfizer Inc. to enhance outcomes for lymphoma patients by evaluating ADCETRIS (brentuximab vedotin). Under this collaboration, Pfizer holds commercialization rights for ADCETRIS in the U.S. and Canada, while Takeda retains rights for the rest of the world and manages regulatory filings outside of the U.S. Pfizer Inc. is a US-based developer of ADCETRIS for the treatment of anaplastic lymphoma.

Major companies operating in the anaplastic large cell lymphoma therapeutics market are Pfizer Inc. , Bristol‑Myers Squibb Company , Kyowa Kirin Co. Ltd. , Genmab A/S , Novartis AG , Takeda Pharmaceutical Company Limited , Merck & Co. Inc. , AbbVie Inc. , Gilead Sciences Inc. , Amgen Inc. , Regeneron Pharmaceuticals Inc. , BeiGene Ltd. , BioCryst Pharmaceuticals Inc. , Acrotech Biopharma Inc. , Citius Pharmaceuticals Inc. , Prescient Therapeutics Ltd. , Autolus Therapeutics Plc , AstraZeneca Plc , Daiichi Sankyo Company Limited , Verastem Inc. , Innate Pharma SA , Affimed GmbH , Eisai Co. Ltd. , Adaptimmune Therapeutics PLC , Cellectis SA.

North America was the largest region in the anaplastic large cell lymphoma therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anaplastic large cell lymphoma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anaplastic large cell lymphoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the anaplastic large cell lymphoma therapeutics market by increasing costs associated with imported biologics, active pharmaceutical ingredients, specialized manufacturing equipment, and cold-chain logistics used in oncology drug production. North America and Europe are most affected due to dependence on global pharmaceutical supply chains, while Asia-Pacific faces pricing pressure on biologic drug manufacturing inputs. These tariffs are contributing to higher treatment costs and extended timelines for therapy availability. However, they are also encouraging domestic biologics manufacturing, regional clinical development, and long-term investment in localized oncology drug production capabilities.

The anaplastic large cell lymphoma therapeutics market research report is one of a series of new reports that provides anaplastic large cell lymphoma therapeutics market statistics, including anaplastic large cell lymphoma therapeutics industry global market size, regional shares, competitors with a anaplastic large cell lymphoma therapeutics market share, detailed anaplastic large cell lymphoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the anaplastic large cell lymphoma therapeutics industry. This anaplastic large cell lymphoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anaplastic large cell lymphoma (ALCL) therapeutics include various treatment strategies aimed at managing this rare and aggressive T-cell non-Hodgkin lymphoma (NHL). The primary objectives are to eliminate malignant T-cells, achieve remission, reduce the risk of relapse, and minimize adverse effects.

The main disease categories for ALCL therapeutics are primary anaplastic large cell lymphoma and relapsed anaplastic large cell lymphoma. Primary ALCL is an aggressive form of non-Hodgkin lymphoma characterized by abnormal T-cell proliferation, often affecting lymph nodes or skin, and is typically treated with chemotherapy regimens such as CHOP to improve outcomes. Treatment options include chemotherapy, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), brentuximab vedotin, pralatrexate, surgery, radiation therapy, and stem cell transplantation, with applications in both inpatient and outpatient settings.

The anaplastic large cell lymphoma therapeutics market consists of revenues earned by entities by providing services such as immunotherapy, supportive care and symptom management, personalized treatment planning, post-treatment monitoring, and relapse prevention. The anaplastic large cell lymphoma therapeutics market also includes sales of antibody-drug conjugates and chemotherapy agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.